Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality Allan Linneberg, MD, PhD, Rikke Kart Jacobsen, MSc, Lasse Jespersen, MD, Steen Z. Abildstrøm, MD, PhD Journal of Allergy and Clinical Immunology Volume 129, Issue 2, Pages 413-419 (February 2012) DOI: 10.1016/j.jaci.2011.09.007 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Number of persons (yellow bars) included in the SCIT group by the calendar year in which they claimed their first prescription for allergen extract for SCIT from the start of the Danish National Prescription Registry in 1995 and through 2006. The figure also shows the number of persons (blue bars) included in the SCIT group by calendar year when excluding persons who claimed a prescription for SCIT extracts in 1995 or 1996, thereby providing more valid figures of new-incident users of SCIT for each calendar year from 1997 to 2006. Journal of Allergy and Clinical Immunology 2012 129, 413-419DOI: (10.1016/j.jaci.2011.09.007) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions